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A careful balance between the inﬂammatory and anti-
inﬂammatory response is vital in order to survive the 
daily invasion of pathogens. Sepsis has always been 
regarded as the result of an exacerbated detrimental 
inﬂammatory response towards invading bacteria. 
However, recent insights have forced us to rethink this 
sepsis paradigm. This review discusses the latest trends 
and developments in the sepsis ﬁeld and helps to set 
the stage for the current debate on whether the sepsis 
response is good or bad.
Introduction
Sepsis is clinically defined as an infection with evidence 
of systemic inflammation, as reflected by increased or 
decreased temperature or leukocyte count, tachycardia, 
and rapid breathing [1,2•]. This formal definition tries 
to cover the clinical syndrome that results from an over-
whelming systemic host response to infection [1,2•]. Both 
the incidence of sepsis and the number of sepsis-related 
deaths are increasing: in the United States the incidence 
of sepsis is 240 per 100,000 population, making sepsis 
the 10th leading cause of death overall [3]. The increased 
use of invasive procedures, immunosuppressive therapy, 
chemotherapy, and organ transplantation, as well as the 
HIV epidemic and increasing microbial resistance are all 
recognized as potential reasons for the increased incidence 
of sepsis [3]. One problem with clinical trials of novel 
sepsis therapies is that the patients are notoriously hetero-
geneous with respect to the inciting cause of their disease, 
the comorbid conditions that define its course, and the 
acute severity of their initial presentation [4,5]. These 
major differences among patients in clinical sepsis trials 
have given rise to a remarkable variety in mortality risks 
across studies and probably to variable response rates to 
given interventions [4]. These observations and the failure 
of virtually all clinical sepsis trials have led to a rethink-
ing of the true definition of sepsis. Often, the explanation 
of sepsis is oversimplified as just the result of exacerbated 
inflammatory responses. A 2003 consensus meeting of sep-
sis experts tried to tackle this problem but concluded that 
no evidence exists to support changing the original 1992 
consensus meeting definitions. The 2003 consensus found 
that apart from expanding the list of signs and symptoms 
of sepsis to reflect clinical bedside experience, the lack of 
evidence underscores the continuing challenge in diagnos-
ing sepsis today [1]. In recent years, exciting advances have 
been made in understanding sepsis pathogenesis, from the 
initial recognition of the invading pathogen to the counter-
acting host response. These new insights provide us with 
a steady stream of new potential treatment targets. This 
review examines the latest trends and developments in the 
sepsis field and aims to help set the stage for the current 
debate about whether the sepsis response is good or bad.
Toll-like Receptors 
and the Inflammatory Response 
Toll-like receptors and pathogen recognition
Pathogens that attack the host are initially recognized by 
the innate immune system through pattern-recognition 
receptors (PRRs) [6]. One family of PRRs, the recently 
discovered class of Toll-like receptors (TLRs), has emerged 
as the central line of defense against invading microbes 
(Fig. 1). TLRs are the first to detect host invasion by 
pathogens, initiate immune responses, and form the cru-
cial link between the innate and adaptive immune systems 
[6]. TLRs together with other PRRs enable the innate 
immune system to discriminate potential pathogens from 
self by recognizing conserved motifs on pathogens that 
are not found in higher eukaryotes. Examples of these so-
called pathogen-associated molecular patterns (PAMPs), 
include lipopolysaccharide (LPS) from the outer mem-
brane of gram-negative bacteria, peptidoglycan (present 
in most bacteria), lipoteichoic acid (in many gram-positive 
bacteria), and mannans in the yeast cell wall. Ligands for 
10 mammalian TLRs have been described (11 in mice). It 
must be emphasized that the TLRs function in a coordi-
nated manner; different components of one microorganism 
are recognized by different TLRs. Escherichia coli, for 
example, is a gram-negative bacterium expressing sev-
eral PAMPs (peptidoglycan, LPS, flagellin, and bacterial 
DNA), which are all recognized by different TLRs (TLR2, 
TLR4, TLR5, and TLR9, respectively). Given their central 
role in the recognition of microbes, it is rational to hypoth-
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esize that TLRs play a central role in sepsis pathogenicity. 
Indeed, animals lacking the gene encoding TLR4 do not 
develop shock in response to LPS [6]. Although LPS is 
the best studied and probably most important mediator 
of sepsis, peptidoglycan, lipoteichoic acid, bacterial CpG 
DNA, and flagella are other important microbial products 
implicated in the pathogenesis of sepsis. All these PAMPs 
signal through different TLRs. As a result, the relationship 
between TLR expression and human sepsis is complex.
In recent years, TLR2 has been recognized as the 
gram-positive TLR because of its ability to sense major 
gram-positive cell wall components such as peptidoglycan 
and lipoteichoic acid, whereas TLR4, the LPS receptor, 
is seen as the gram-negative TLR. However, as more 
knowledge about the precise role TLRs in different bac-
teria becomes available, this concept should be modified. 
For instance, Streptococcus pneumoniae is sensed by the 
innate immune system, not only through TLR2, which 
recognizes lipoteichoic acid and peptidoglycan, but also 
through TLR4, which recognizes pneumolysin. It was 
recently shown that TLR2 is indispensable for alveolar 
macrophage responsiveness toward S. pneumoniae [7]. 
However, in the same study, TLR2 gene-deficient mice 
intranasally inoculated with nonlethal to lethal doses of 
S. pneumoniae displayed only a modestly reduced inflam-
matory response in their lungs and showed an unaltered 
antibacterial defense and survival in comparison with 
wild-type mice [7]. These data suggest that the function 
of TLR2 in the innate immune response to S. pneumoniae
is limited. Clearly, other PRRs play an important role. 
The LPS-TLR4 interaction appears to be of eminent 
importance for the induction of an adequate immune 
response, as illustrated by an impaired host defense of 
TLR4-deficient mice during gram-negative infection 
[8,9]. Overall, given their central role in the recognition 
of microbes, TLRs clearly play a crucial role in sepsis. In 
this respect, one must consider that on one hand, TLRs 
are essential for the early detection of pathogen, but on 
the other hand, they may also cause excessive inflamma-
tion after uncontrolled stimulation. TLRs may further 
contribute to the pathogenesis of sepsis by amplifying 
inflammatory responses by interaction with endogenous 
mediators released during injurious processes such as 
trauma, ischemia, or necrosis. For the recognition of such 
endogenous danger signals, which have been named 
alarmins or danger-associated molecular patterns, TLR4 
seems to be of particular importance [10].
Cytokines and systemic inflammatory response
Activation of TLRs and other PRRs will result in the 
release of a multitude of cytokines, which have a prime 
role in the pathogenesis of sepsis by coordinating a wide 
variety of inflammatory reactions at the tissue level and 






















Figure 1. Toll-like receptors (TLR) and 
pathogen recognition. The TLR family 
discriminates between speciﬁc patterns of 
microbial components. TLR2, which can 
associate with TLR1 and TLR6, is essential 
for the recognition of microbial lipopeptides. 
TLR4 recognizes lipopolysaccharide (LPS). 
LPS ﬁrst binds to LPS-binding protein (LBP), 
which transfers LPS to CD14. Binding of LPS 
to CD14 leads to the association of CD14 
with MD2 and TLR4. TLR5 is a receptor for 
ﬂagellin. TLR9 is the CpG DNA receptor, 
whereas TLR3 and TLR7 are implicated in 
the recognition of viral double-stranded 
RNA (dsRNA) and single-stranded RNA 
(ssRNA), respectively. After TLR stimulation, 
the adaptor molecule myeloid differentia-
tion primary-response protein 88 (MyD88) 
is recruited. This will lead to the release of 
nuclear factor (NF)-LB, which will result 
in the transcription of a whole range of 
inﬂammatory genes. Next to MyD88, the 
adaptor molecules Toll/interleukin receptor 
(TIR) domain-containing adaptor protein 
(TIRAP), TIR domain-containing adaptor 
protein-inducing interferon-C (TRIF), and 
TRIF-related adaptor molecule (TRAM) 
have been identiﬁed. TIRAP is essential for 
MyD88-dependent signaling through TLR2 
and TLR4. TRIF is essential for the TLR3- and 
TLR4-mediated activation of the MyD88-




Classic proinflammatory cytokines such as interleukin 
(IL)-1, IL-6, tumor necrosis factor (TNF)-B, IL-12, IL-15, 
and IL-18 will activate both humoral and cellular host 
defense mechanisms. Anti–TNF-B treatment reduces mor-
tality in primate models of overwhelming sepsis induced 
by intravenous administration of bacteria [11]. In addition, 
neutralization of IL-1 also reduced lethality in animal mod-
els of sepsis [12]. However, subsequent clinical sepsis trials 
targeting these “magic bullets” such as TNF-B and/or 
IL-1 failed to demonstrate a clinical benefit in patients with 
sepsis. These failures likely are related to multiple factors. 
In this respect, it is good to realize that the primate sepsis 
model (intravenous infusion of high doses of bacteria) used 
in the preclinical phase of several immunomodulatory sep-
sis drugs does not mimic human sepsis in the intensive care 
unit. In addition, local activity of proinflammatory cyto-
kines at the site of the infection contributes to host defense 
in experimental models of the two most common causes of 
sepsis, pneumonia and peritonitis [13].
C5a and the complement pathway
The complement system, which consists of approximately 
30 plasma proteins, can be activated by three different 
pathways, the classical, alternative, and lectin-binding 
pathways, all of which lead to cleavage of C3 and C5 into 
the powerful proinflammatory peptides C3a and C5a 
[14•]. Although the complement system has tradition-
ally been viewed as an essential part of the host defense 
against invading microbes, complement activation has 
recently been implicated in the pathogenesis of sepsis 
[14•]. In sepsis, the appearance of C5a in the blood indi-
cates a loss of control of complement activation, leading 
to degradation of the innate immune defenses [14•]. The 
important role of C5a in sepsis pathogenesis has been 
underlined by recent studies in rodents: C5 gene–deficient 
mice show less inflammation upon stimulation with LPS 
compared to wild-type mice [14•], and treatment with 
anti-C5a antibodies partially protected rats from cecal 
ligation and puncture (CLP)-induced sepsis [15].
Counter-inflammatory Response
The proinflammatory response in sepsis, induced by the 
initial recognition of the invading pathogens by TLRs, 
is balanced by a counter-regulatory response that tries 
to restore immunologic equilibrium. This counter-
inflammatory response includes among others a vast 
system of negative regulators of TLR signaling, a shift 
from inflammatory (T-helper 1) to anti-inflammatory 
(T-helper 2) cytokine production, together with apoptosis 
of immune effector cells, resulting in a well-orchestrated 
suppression of the immune system [16]. 
Negative regulators of the TLR-signaling cascade
The entire TLR family signals via four adapter proteins 
(ie, myeloid differentiation primary response protein 88 
[MyD88], Toll/IL-1 receptor [TIR] domain-containing 
adaptor protein, TIR domain-containing adaptor protein 
inducing interferon-C [TRIF], and TRIF-related adap-
tor molecule [TRAM]), which together take care of the 
response to a whole universe of microbial molecules (Fig. 1) 
[6]. MyD88 is involved in the signaling of all TLRs except 
TLR3. After TLR stimulation, MyD88 associates with 
IL-1 receptor-associated kinase (IRAK) 4, resulting in the 
phosphorylation of IRAK1. Negative regulation of this 
TLR signaling pathway is essential [17]. In the cytoplasm, 
IRAK-M inhibits the dissociation of the IRAK1-IRAK4 
complex from the receptor, suppressor of cytokines signal-
ing-1 probably directly inhibits IRAK1, and a short form 
of MyD88 blocks the association of IRAK4 with MyD88. 
On the cell membrane, other members of the TIR super-
family such as single immunoglobulin IL-1 receptor-related 
molecule and ST2 also negatively modulate TLR signaling 
[18,19]. Other mechanisms by which TLR signaling can 
be controlled include the reduction of TLR expression by 
TLR degradation or inhibition by anti-inflammatory cyto-
kines. Furthermore, TLRs clearly can function as death 
receptors; this TLR-induced apoptosis may be important 
in the control of a dysregulated TLR response [17].
Immunoparalysis and apoptosis
In clinical sepsis, the early host response, which is charac-
terized by hyperinflammation, is followed by a phase of 
hyporesponsiveness and immunodepression (also referred to 
as immunoparalysis). Important cytokines with mostly anti-
inflammatory profiles are IL-1 receptor-antagonist, IL-4, 
IL-10, and transforming growth factor-C, as well as soluble 
TNF receptors. Monocytes, granulocytes, and lymphocytes 
of patients with sepsis show a diminished responsiveness 
after restimulation with bacterial antigens, as indicated by 
a diminished cytokine release [16,20]. Although immuno-
paralysis has been regarded as beneficial in the sense that 
it counteracts a potentially devastating proinflammatory 
response, it can also lead to an inability to clear infection and 
a subsequent predisposition to nosocomial infection [16]. 
Recent work has gained insight into the mechanisms of 
immune suppression in sepsis. The mentioned shift to anti-
inflammatory cytokines is an important factor. Furthermore, 
Hotchkiss et al. [21•] have shown that large numbers of 
lymphocytes and gastrointestinal epithelial cells die by apop-
tosis during sepsis. By committing suicide, these immune 
cells probably dampen the inflammatory response by simply 
reducing the amount of circulating immune cells and induc-
ing the release of anti-inflammatory cytokines. Prevention of 
lymphocyte apoptosis improves the likelihood of survival in 
animal models of sepsis, illustrating the importance of lym-
phocyte depletion in this syndrome [16,22,23].
Vagus nerve and the nicotinic 
anti-inflammatory pathway 
Another physiologic anti-inflammatory mechanism that 
has recently emerged as an important control system of 
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the inflammatory response is the vagus nerve. This cranial 
nerve that innervates most of the peripheral organs can 
downregulate inflammation by decreasing the release of 
TNF-B, IL-1, IL-6, and high-mobility group box (HMGB) 
1 protein by LPS-stimulated macrophages [24]. This anti-
inflammatory effect is mediated by an interaction between 
acetylcholine, the principal neurotransmitter of the vagus 
nerve, and the B7-nicotinic acetylcholine receptors on 
macrophages [24,25]. In studies of experimental endotox-
emia in rats, surgical dissection of the vagus nerve led to 
enhanced systemic TNF-B production and accelerated the 
development of shock. In turn, electrical stimulation of the 
vagus nerve downregulated TNF-B production and pro-
tected the animals from hypotension [24]. 
Excitingly, treatment with nicotine, which is a ligand 
for the B7-nicotinic acetylcholine receptor, reduced circu-
lating TNF-B and HMGB-1 levels and improved survival 
in experimental sepsis in rodents [24,25,26•]. Further evi-
dence for the role of the vagus nerve as an anti-inflammatory 
mediator in sepsis comes from a murine study in which the 
cytokine release in septic peritonitis was enhanced after 
previous vagotomy and decreased after nicotine pretreat-
ment [27]. Central muscarinic receptors within the brain 
play a role in activating the cholinergic anti-inflammatory 
pathway [28]. Moreover, the spleen is an essential periph-
eral part of the cholinergic anti-inflammatory reflex [29]. 
Together, these preclinical data suggest that stimulation 
of the vagus nerve and/or pharmacologic B7 cholinergic 
receptor agonists may be a useful strategy in the treatment 
of the severe inflammation accompanying sepsis. 
Dysbalance between Coagulation 
and Anticoagulation
Activation of the coagulation pathway is an impor-
tant event in the pathogenesis of sepsis. Activation of 
coagulation and deposition of fibrin as a consequence of 
inflammation can be considered instrumental in contain-
ing inflammatory activity to the site of infection. However, 
inflammation-induced coagulation may be detrimental in 
those circumstances when the triggered blood coagulation 
system is insufficiently controlled, which can lead to the 
clinical syndrome of disseminated intravascular coagula-
tion and microvascular thrombosis [30,31]. A simplified 
overview of the interactions between coagulation and 
inflammation is presented in Figure 2 [31].
Tissue factor and activation of coagulation 
Tissue factor (TF) is constitutively expressed by different 
cell types in the extravascular compartment (eg, pericytes, 
cardiomyocytes, smooth muscle cells, and keratinocytes), 
whereas monocytes and endothelial cells will only start 
expressing TF during severe inflammation [30,31]. TF is 
one of the primary initiators of the inflammation-induced 
coagulation cascade [30,31]. Interaction of TF with factor 
VIIa, which circulates at low levels in the bloodstream, 
results in the activation of factor X either directly or 
indirectly through the activation of factor IX. Activated 
factor X converts prothrombin (factor II) to thrombin, 
which finally induces the conversion of fibrin to fibrino-
gen, thereby inducing the formation of a blood clot. 
The pivotal role of TF in activation of coagula-
tion during sepsis has been established by many 
different experiments. The generation of thrombin in 
humans intravenously injected with a low dose of endo-
toxin, documented by a rise in the plasma concentrations 
of the prothrombin fragment F1+2 and of thrombin-
antithrombin complexes, was preceded by an increase 
in TF messenger RNA levels in circulating blood cells, 
enhanced expression of TF on circulating monocytes, and 
the release of TF-containing microparticles [32,33]. A 
number of different strategies prevent the activation of the 
VIIa-TF pathway in endotoxemic humans and chimpan-
zees and abrogate the activation of the common pathway 
of coagulation in bacteremic baboons. In healthy humans 
injected with LPS, intravenous infusion of recombinant 
TF pathway inhibitor (TFPI) caused a dose-dependent 
inhibition of coagulation activation [34]. Strategies that 
potently inhibited coagulation activation in endotoxemic 
or bacteremic primates include antibodies directed against 
TF or factor VII/VIIa and TFPI [30,31,35,36].
Anticoagulant mechanisms
Activation of coagulation and the resulting generation of 
fibrin is counterbalanced by anticoagulant mechanisms, 
in particular TFPI, antithrombin, activated protein C 
(APC), and the fibrinolytic system [30,31]. TFPI is a pro-
tease inhibitor primarily produced by endothelial cells 
that inactivates factor VIIa bound to TF. Antithrombin 
inhibits factor Xa, thrombin, and factor IXa, as well as 
factor VIIa bound to TF. The protein C system provides 
important control of coagulation by virtue of the capac-
ity of APC to inactivate factors Va and VIIIa, thereby 
preventing the procoagulant activities of factors Xa and 
IXa. Protein S serves as an essential cofactor for APC. In 
the protein C system, thrombin functions as an antico-
agulant. This pathway is triggered when thrombin binds 
to the endothelial cell receptor thrombomodulin [30,37]. 
Thrombomodulin inhibits coagulation by conversion of 
thrombin into an activator of protein C via the endothe-
lial protein C receptor. 
Several preclinical studies have supported the antico-
agulant potencies of TFPI, antithrombin, and the protein 
C system in vivo. Infusion of either TFPI, antithrombin, 
or APC attenuated consumptive coagulopathy in septic 
primates [35,38,39], and inhibition of activation of endog-
enous protein C by a monoclonal antibody exacerbated the 
response to a lethal E. coli infusion [39]. In the Recombi-
nant Human Activated Protein C Worldwide Evaluation in 
Severe Sepsis (PROWESS) study, in which 1690 patients 
with severe sepsis were randomized to receive APC or pla-
cebo, APC reduced morbidity and mortality [40]. 
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Hemostasis is further controlled by the fibrinolytic 
system in which plasmin plays a key in the degradation 
of fibrin. Plasmin is generated from plasminogen by a 
series of proteases, most notably tissue-type plasminogen 
activator and urokinase-type plasminogen activator. The 
main inhibitor of plasminogen activator is plasminogen 
activator inhibitor (PAI)-1, which binds to tissue-type 
plasminogen activator and urokinase-type plasminogen 
activator. Plasma concentrations of PAI-1 are elevated in 
patients with sepsis and are predictive of unfavorable out-
come in sepsis patients [41].
Disturbance of the balance between coagulation 
and anticoagulation
Severe sepsis is characterized by activation of TF-
dependent coagulation with concurrent inhibition of 
anticoagulant mechanisms: TF procoagulant activity is 
markedly enhanced, whereas the activities of TFPI, anti-
thrombin, the protein C–APC system, and fibrinolysis are 
all impaired, resulting in a shift toward a net procoagulant 
state [42]. The impairment of the protein C system during 
sepsis is the result of increased consumption of protein S 
and protein C and decreased activation of protein C by 
downregulation of thrombomodulin on endothelial cells. 
Finally, fibrinolysis is impaired in sepsis, primarily due to 
exaggerated release of PAI-1 [30,31,41].
New Actors in the Sepsis Theater
High-mobility group box 1 protein
HMGB-1 functions as a late-acting proinflammatory medi-
ator of sepsis, and it circulates in high concentrations in the 
majority of septic patients [43,44]. It is secreted by activated 
immune cells and elicits prolonged activation of cells, either 
directly or more likely indirectly via substances bound to 
HMGB1, via the receptor for advanced glycation end prod-
ucts, TLR2, and TLR4 [45]. LPS stimulation was found to 
mediate the expression of HMGB-1 from macrophages at 
a considerably later stage than the release of the proinflam-
matory cytokines TNF-B and IL-1 [44]. Administration of 
HMGB-1 itself is lethal to mice, whereas the administration 



























Figure 2. Simpliﬁed overview of the bidirectional relation between inﬂammation and coagulation in sepsis. 1, Invading pathogens are rec-
ognized by the immune system through Toll-like receptors (TLRs). After recognition, the coagulation cascade is activated by inducing tissue 
factor (TF) expression on monocytes and granulocytes. In sepsis, decreased levels of free protein S and activated protein C (APC) are seen, 
ultimately leading to enhanced thrombin formation. 2, A ﬁbrin clot with activated mononuclear cells is formed. In severe cases, this may 
lead to disseminated intravascular coagulation. 3, The activated counteracting plasmin-mediated ﬁbrinolysis leads to the formation of ﬁbrin 
degradation products (FDP). 4, Furthermore, after binding to urokinase plasminogen activator (uPA), the upregulated uPA receptor (uPAR) on 
monocytes and granulocytes will enhance the ﬁbrinolytic pathway. Plasminogen activator inhibitor (PAI)-1, which is strongly upregulated in 
sepsis, inhibits these ﬁbrinolytic events. 5, Binding of among other TF and thrombin to speciﬁc protease-activated receptors on inﬂammatory 
cells may affect inﬂammation by inducing release of proinﬂammatory cytokines, which will further modulate coagulation and ﬁbrinolysis. 
Straight and dashed arrows indicate stimulatory and inhibitory effects, respectively. IL—interleukin; NF—nuclear factor; TAFI—thrombin 
activatable ﬁbrinolysis inhibitor; TFPI—tissue factor pathway inhibitor; TM—thrombomodulin; TNF—tumor necrosis factor; tPA—tissue-type 
plasminogen activator. (Adapted from Wiersinga et al. [31].)
Is the Septic Response Good or Bad? Wiersinga and van der Poll 371
[44]. As mentioned above, stimulation of the cholinergic 
anti-inflammatory pathway with nicotine inhibits both LPS- 
and TNF-B–mediated release of HMGB-1 [26•]. Nicotine 
attenuates serum HMGB-1 levels, paralleling improved 
survival in experimental models of sepsis. Of significance, 
encouraging results were seen in sepsis models, even when 
anti–HMGB-1 treatment was started at a late stage.
Triggering receptor expressed on myeloid cells 1
Triggering receptor expressed on myeloid cells (TREM)-
1 amplifies the TLR-mediated inflammatory response to 
microbial products [46]. TREM-1, which signals through 
the adaptor protein DAP12, is strongly and specifically 
expressed on monocytes and neutrophils from patients with 
sepsis [46]. Of diagnostic importance, high concentrations 
of plasma-soluble TREM-1 can indicate infection in patients 
with systemic inflammatory response syndrome [47]. 
Excitingly, blockade of TREM-1 protects mice against LPS-
induced shock, as well as microbial sepsis caused by live E. 
coli or CLP [46]. In addition, a synthetic peptide mimicking 
a short, highly conserved domain of soluble TREM-1 pro-
tected septic animals from hyper-responsiveness and death 
[48•]. Intriguingly, although TREM-1 signals through the 
adaptor protein DAP12 [46], a recent study showed that 
DAP12-deficient mice have—contrary to what would be 
expected—enhanced TLR responses in vitro, as indicated 
by an enhanced production of proinflammatory cytokines 
of DAP12-deficient macrophages in response to TLR ago-
nists, and in vivo, as indicated by an increased susceptibility 
to endotoxic shock [49]. Perhaps certain DAP12-associated 
receptors function as negative regulators of TLR responses.
Macrophage migration inhibitory factor
In recent years, macrophage migration inhibitory factor 
(MIF) has emerged as a pivotal regulator of innate immunity 
that has been implicated in sepsis pathogenesis [50,51]. MIF 
regulates innate immune responses through modulation of 
TLR4: when MIF-deficient mice are challenged with LPS, 
they show a defective response as a direct result of decreased 
TLR4 expression [50]. In patients, MIF levels correlate with 
fatal outcome in sepsis [52]. MIF-directed therapies might 
offer a new treatment opportunity for sepsis. Inhibition of 
MIF activity with neutralizing anti-MIF antibodies protected 
mice from septic shock [51]. Furthermore, a specific small 
molecule inhibitor of MIF, named ISO-1, partially protected 
mice from sepsis induced by endotoxin or CLP [53]. 
Conclusions 
A careful balance between the inflammatory and anti-
inflammatory response is vital in order to survive the 



































Figure 3. Invasion of bacteria and the septic 
response: the pro- and anti-inﬂammatory 
pathways in sepsis. Invading bacteria 
are recognized by pathogen recognition 
receptors, such as the Toll-like receptor 
(TLR) and nucleotide-binding oligodimeriza-
tion domain (NOD) proteins, after which 
a proinﬂammatory response is initiated via 
nuclear factor (NF)-LB. Next to the release 
of proinﬂammatory cytokines, the antibacte-
rial response is characterized by activation 
of both the complement and coagulation 
systems. Triggering receptor expressed 
on myeloid cells (TREM)-1 serves as an 
ampliﬁer of the TLR-initiated inﬂammatory 
response. The counteracting anti-inﬂamma-
tory response is subsequently characterized 
by negative regulators of the TLRs such 
as ST2, the release of anti-inﬂammatory 
cytokines, apoptosis of lymphocytes, 
activation of the nicotinic anti-inﬂammatory 
pathway, and the release of anticoagulant 
proteins. Eventually, the balance between 
the pro- and anti-inﬂammatory reactions 
will determine the outcome of the septic 
response. B7nAChR—B7-nicotinic ace-
tylcholine receptor; APC—active protein 
C; HMGB-1—high-mobility group box 
1 protein; IL—interleukin; IL-1RA—IL-1 
receptor antagonist; IRAK-M—IL-1 recep-
tor–associated kinase M; MyD88—myeloid 
differentiation primary-response protein 88; 
TGF—transforming growth factor; TF—tissue 
factor; TFPI—tissue factor pathway inhibitor; 
TNF—tumor necrosis factor.
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been regarded as the result of an exacerbated detrimental 
inflammatory response toward invading bacteria. How-
ever, recent insights described in this review have forced 
us to rethink this sepsis paradigm. Indeed, septic patients 
can die from the initial exacerbated hyperinflammatory 
response, but remarkably, most patients will succumb 
during the following extended period of immunodepres-
sion [21•]. Likewise, sepsis will cause triggering of the 
coagulation system while diminishing the activity of both 
natural anticoagulant mechanisms and the fibrinolytic 
system. Augmented interactions between inflammation 
and coagulation can give rise to a vicious cycle, eventu-
ally leading to dramatic events such as those manifested 
in severe sepsis and disseminated intravascular coagula-
tion. Taken together, one can state that without a good 
inflammatory response toward invading bacteria, all will 
succumb; however, too good of a septic response can lead 
to a fatal outcome.
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